Early cancer detection from liquid biopsy
Floating Genes is developing the NGS-based targeted sequencing technology “Enhance-seq” to detect rare mutations (patent submitted). Enhance-seq is highly sensitive to detect few molecules of rare circulating tumor DNA (ctDNA) in a strong background of non-mutated DNA with a low sequencing depth.
Founded in 2021 by Dipanwita Biswas and Gabriel Lerebours, Floating Genes is incubated in Paris Biotech Santé, and accompanied by Wilco. A proof of concept of the technology has been conducted in the Shaker program of Genopole.
Floating Genes aims at improving early cancer diagnosis with highly sensitive NGS-based technology. The company is developing in vitro diagnosis tests based on liquid biopsy.